Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

CrowdStrike rallied alongside cybersecurity peers as AI-discovered vulnerabilities, including critical PHP flaws that disrupted websites, sharpened concerns about cyber threats and the need for protection. Buyers see the incidents as a tailwind for security spending, while skeptics argue the stocks valuation is already stretched.

BioNTechs planned founder departures and weak revenue outlook are fueling concerns about leadership and its post-COVID business, compounded by setbacks in cancer-vaccine trials. Bulls counter that the companys cash reserves and broader oncology pipeline still offer potential, leaving debate over whether the clinical setbacks undermine the long-term story.

CASHCAT is drawing attention for its sharp, volatile swings after a major rally and steep pullbacks, with traders debating whether dips are buying opportunities or signs of a pump-and-dump. Bulls point to its Robinhood-chain and meme-coin ecosystem narrative, while skeptics question its utility and warn of further losses; claims of manipulation and short squeezes remain speculation.

Lillys share-price momentum and anticipation of Q3 results dominate, with bullish traders pointing to demand for Mounjaro and Zepbound, expanding oral-drug prospects, and analyst optimism. Others question the premium valuation and warn that GLP-1 competition or profit-taking could stall the run; pipeline news adds interest but is a secondary theme.

Caterpillars sharp pullback ahead of its quarterly report is driving debate, despite traders pointing to a record backlog and data-center power demand. Some see an oversold buying opportunity, while others expect further weakness if results or guidance fail to meet high expectations.

Whirlpools weak Q1 results, sharply reduced full-year outlook and suspension of its dividend amid recession-level appliance demand have driven a steep selloff. Traders debate whether the pressure reflects broader consumer and housing weakness or years of management and debt problems, with some calling the shares a value opportunity while others fear further declines or bankruptcy.

AXSM is under pressure as investors question whether Auvelitys launch for Alzheimers-related agitation is gaining traction, with prescription data and sales-force execution under scrutiny ahead of the Q3 results. Traders disagree on whether reported scripts undercount demand from samples and long-term-care facilities or point to a slower-than-expected ramp, while managements silence has added to uncertainty.

Attention centers on Teladocs upcoming quarterly results and whether its BetterHelp shift from cash-pay to insurance can stabilize the business after weaker guidance. Bulls point to a possible rebound and heavily shorted shares, while bears question managements execution and expect continued business weakness.

Ethereum is drawing attention amid a volatile pullback alongside broader crypto weakness, with traders focused on whether nearby support will hold or give way to further losses. Bears warn of more downside, while dip buyers point to accumulation and see the weakness as a potential reversal setup.

ARKK is drawing attention as traders debate whether its attempt to break out of a prolonged growth-stock slump can hold. Bulls point to improving technicals and renewed interest in high-beta names, while skeptics cite the funds history of underperformance and question Cathie Woods portfolio decisions.